178 related articles for article (PubMed ID: 18424761)
1. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia.
Friedrichs B; Siegel S; Kloess M; Barsoum A; Coggin J; Rohrer J; Jakob I; Tiemann M; Heidorn K; Schulte C; Kabelitz D; Steinmann J; Schmitz N; Zeis M
J Immunol; 2008 May; 180(9):6374-84. PubMed ID: 18424761
[TBL] [Abstract][Full Text] [Related]
2. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
3. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma.
Zelle-Rieser C; Barsoum AL; Sallusto F; Ramoner R; Rohrer JW; Höltl L; Bartsch G; Coggin JH JR; Thurnher M
J Urol; 2001 May; 165(5):1705-9. PubMed ID: 11342960
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.
Griggio V; Mandili G; Vitale C; Capello M; Macor P; Serra S; Castella B; Peola S; Foglietta M; Drandi D; Omedé P; Sblattero D; Cappello P; Chiarle R; Deaglio S; Boccadoro M; Novelli F; Massaia M; Coscia M
Oncotarget; 2017 Jan; 8(2):3274-3288. PubMed ID: 27906678
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
6. High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia.
Friedrichs B; Siegel S; Reimer R; Barsoum A; Coggin J; Kabelitz D; Heidorn K; Schulte C; Schmitz N; Zeis M
Leuk Res; 2011 Jun; 35(6):721-9. PubMed ID: 21055809
[TBL] [Abstract][Full Text] [Related]
7. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
Baskar S; Suschak JM; Samija I; Srinivasan R; Childs RW; Pavletic SZ; Bishop MR; Rader C
Blood; 2009 Nov; 114(20):4494-502. PubMed ID: 19667400
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
[TBL] [Abstract][Full Text] [Related]
9. Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression.
Criado I; Muñoz-Criado S; Rodríguez-Caballero A; Nieto WG; Romero A; Fernández-Navarro P; Alcoceba M; Contreras T; González M; Orfao A; Almeida J;
Haematologica; 2017 Jul; 102(7):1238-1246. PubMed ID: 28385786
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.
McClintock SD; Warner RL; Ali S; Chekuri A; Dame MK; Attili D; Knibbs RK; Aslam MN; Sinkule J; Morgan AC; Barsoum A; Smith LB; Beer DG; Johnson KJ; Varani J
Cancer Biol Ther; 2015; 16(5):724-32. PubMed ID: 25799942
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.
Crassini KR; Zhang E; Balendran S; Freeman JA; Best OG; Forsyth CJ; Mackinlay NJ; Han P; Stevenson WS; Mulligan SP
Br J Haematol; 2018 Apr; 181(1):97-101. PubMed ID: 29468645
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
Khouri IF; Bassett R; Poindexter N; O'Brien S; Bueso-Ramos CE; Hsu Y; Ferrajoli A; Keating MJ; Champlin R; Fernandez-Vina M
Cancer; 2011 Oct; 117(20):4679-88. PubMed ID: 21455998
[TBL] [Abstract][Full Text] [Related]
13. SEMG-1 expression in early stage chronic lymphocytic leukemia.
Ahmed SU; Meklat F; Shahriar M; Zhang J; Mastulov S; Giannakouros T; Jewell A; Zhang Y; Lim SH
Cytotherapy; 2009; 11(2):238-44. PubMed ID: 19241194
[TBL] [Abstract][Full Text] [Related]
14. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.
Dreger P; Michallet M; Schmitz N
Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779
[TBL] [Abstract][Full Text] [Related]
15. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
Coggin JH; Barsoum AL; Rohrer JW
Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
[TBL] [Abstract][Full Text] [Related]
16. Broad alterations of self-reactive antibody-repertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity.
Stahl D; Lacroix-Desmazes S; Sibrowski W; Kazatchkine MD; Kaveri SV
Leuk Lymphoma; 2001 Jun; 42(1-2):163-76. PubMed ID: 11699204
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.
Motta M; Rassenti L; Shelvin BJ; Lerner S; Kipps TJ; Keating MJ; Wierda WG
Leukemia; 2005 Oct; 19(10):1788-93. PubMed ID: 16094420
[TBL] [Abstract][Full Text] [Related]
19. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
